NCT06259175 - Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH) | Biotech Hunter

Enrollment

396

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 21, 2025

Study Completion Date

June 1, 2025

Conditions

Arterial HypertensionHTN

Interventions

DRUG

Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg

a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg

a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg

a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

Trial Locations (1)

Unknown

Servier, Moscow

All Listed Sponsors

lead

Servier Russia

INDUSTRY